{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:30:50Z","timestamp":1783794650450,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jceh.2025.102601","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:08:09Z","timestamp":1748459289000},"page":"102601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-4148","authenticated-orcid":false,"given":"Madhumita","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchal","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder","family":"Nain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-1676","authenticated-orcid":false,"given":"Arka","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2025.102601_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: conquering Mount Improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2025.102601_bib2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jceh.2025.102601_bib3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","article-title":"Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program","volume":"167","author":"Premkumar","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.102601_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101148","article-title":"Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the Punjab model","volume":"41","author":"Dhiman","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jceh.2025.102601_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042280","article-title":"Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India","volume":"11","author":"Chugh","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jceh.2025.102601_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jvh.13668","article-title":"Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: a real-world cohort study","volume":"29","author":"Kaur","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2025.102601_bib7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.102601_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","author":"Paolucci","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.jceh.2025.102601_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.jceh.2025.102601_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.101314","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus retreatment in difficult-to-treat patients: a real-life observational study from India","volume":"14","author":"Katiyar","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40258-019-00536-w","article-title":"Cost-effectiveness of therapeutic use of safety-engineered syringes in healthcare facilities in India","volume":"18","author":"Bahuguna","year":"2020","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.jceh.2025.102601_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17474124.2019.1629287","article-title":"High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: a real-life multicenter study","volume":"13","author":"Darweesh","year":"2019","journal-title":"Expet Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","volume":"10","author":"Dietz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2025.102601_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/v14010016","article-title":"The European prevalence of resistance associated substitutions among direct acting antiviral failures","volume":"14","author":"Popping","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jceh.2025.102601_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102717","article-title":"Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure","volume":"26","author":"Rodrigues","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jceh.2025.102601_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.102601_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib22","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jmv.25048","article-title":"Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: impact on current therapeutic strategies","volume":"90","author":"Grandal","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.jceh.2025.102601_bib23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cld.791","article-title":"Recommendations for testing, managing, and treating hepatitis C","volume":"12","year":"2018","journal-title":"Clinical Liver Disease"},{"key":"10.1016\/j.jceh.2025.102601_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fmicb.2019.00535","article-title":"Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in Mainland China","volume":"10","author":"Lu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jceh.2025.102601_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4254\/wjh.v10.i9.543","article-title":"Hepatitis C resistance to NS5A inhibitors: is it going to be a problem?","volume":"10","author":"Sharafi","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.102601_bib28","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.102601_bib29","article-title":"Real-world effectiveness of voxilaprevir\/velpatasvir\/sofosbuvir in patients following DAA failure","volume":"6","author":"Graf","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2025.102601_bib30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2019.06.022","article-title":"High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world","volume":"71","author":"P\u00e9rez","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2023.04.011","article-title":"A randomized-controlled trial of SOF\/VEL\/VOX with or without ribavirin for retreatment of chronic hepatitis C","volume":"79","author":"El-Kassas","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102601_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832500101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832500101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:15:07Z","timestamp":1763399707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S097368832500101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S097368832500101X"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102601","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102601"}}